Brief: Cyclopharm Says Sales Of Technegas In U.S. Expected To Commence In Late 2023
30/03/2023 01:59
March 30 (Reuters) - Cyclopharm Ltd CYC.AX :
* ENTERED FINAL REVIEW PROCESS FOR ATTAINING USFDA APPROVAL
TO
COMMENCE COMMERCIAL SALES OF TECHNEGAS IN US MARKET IN 2023
* EXPECTS TO MAINTAIN ACTIVE DIALOGUE WITH USFDA IN
SIX-MONTH
REVIEW PERIOD
* SALES OF TECHNEGAS IN US ARE EXPECTED TO COMMENCE IN LATE
2023
Source text for Eikon: ID:nASX4Zswjj
Further company coverage: CYC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyclopharm
See all newsAustralia's Cyclopharm rises after Chinese medical groups back its Technegas
Australia's Cyclopharm gains most in 8-months on Technegas rollout deal
Australia's Cyclopharm rises on HY revenue forecast
Brief: Cyclopharm Forecasts 1H Global Revenue Of A$17.1 Million
Brief: Cyclopharm Says David Heaney To Retire As Non-Executive Chair